As of November 7, 2026, Protara Therapeutics, Inc. is a publicly traded company (Nasdaq: TARA); its largest reported holder is Janus Henderson, with 9.6% on Schedule 13G/A of May 15, 2026, then JANUS HENDERSON GROUP Ltd. (8.4%). The largest insider holding is Jesse Shefferman, the chief executive and president, with 991,832 shares (1.6% of shares outstanding), per Form 4 of July 1, 2026 (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Protara Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Protara Therapeutics, Inc. a real, registered company?
- Protara Therapeutics, Inc. files with the SEC under CIK 1359931 (its SEC filings).
- Its shares are listed under the ticker TARA on Nasdaq (SEC company record).
- business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under PROTARA THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Leonardo Viana Nicacio, Chief Medical Officer (Form 8-K filed 2026-06-29). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names JANUS HENDERSON GROUP Ltd. (filed 2026-08-13).
Who are Protara Therapeutics, Inc.'s owners and officers?
Protara Therapeutics, Inc.: business address in New York, New York; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Janus Henderson Group LTD. | 8.4% |
| Schedule 13G/A, 2026-07-07 | Millennium Management LLC | 5.7% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 9.6% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 6.3% |
| Schedule 13G, 2026-03-02 | Millennium Management LLC | 5.1% |
| Schedule 13G/A, 2026-02-17 | Janus Henderson Group PLC | 10% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 4.7% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 11% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 10.6% |
| Schedule 13G/A, 2025-08-14 | Ra Capital Management, L.P. | 4.9% |
| Schedule 13G, 2025-07-17 | Blackrock, Inc. | 5.6% |
Questions about who owns Protara Therapeutics, Inc.
Who owns Protara Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Protara Therapeutics, Inc.: Janus Henderson Group PLC (9.6%, Schedule 13G/A, filed 2026-05-15), Janus Henderson Group LTD. (8.4%, Schedule 13G/A, filed 2026-08-13), Blackrock, Inc. (6.3%, Schedule 13G, filed 2026-04-27) and Millennium Management LLC (5.7%, Schedule 13G/A, filed 2026-07-07).
Who are the largest shareholders of Protara Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Protara Therapeutics, Inc. on this page are Janus Henderson Group PLC (9.6%), Janus Henderson Group LTD. (8.4%) and Blackrock, Inc. (6.3%).
When did Janus Henderson Group PLC buy into Protara Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 10.6%; its latest, Schedule 13G/A filed 2026-05-15, reports 9.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Protara Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Protara Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Protara Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-29 | Leonardo Viana Nicacio | Chief Medical Officer | departed | 2026-06-26 |
Which insiders own Protara Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 991,832 shares (1.6% of shares outstanding), 691,832 held directly and 300,000 indirectly (Form 4, 2026-07-01).
- , the chief r and d officer: 94,827 shares (0.15% of shares outstanding) (Form 4, 2026-04-09).
- , the chief medical officer: 78,181 shares (0.13% of shares outstanding) (Form 4, 2026-01-21).
- , the chief commercial officer: 69,992 shares (0.11% of shares outstanding) (Form 4, 2026-06-03).
- , the chief financial officer: 64,115 shares (0.10% of shares outstanding) (Form 4, 2026-01-27).
Shares outstanding: 61,570,351 as of 2026-11-03, from the company's latest SEC cover page.
How much has Protara Therapeutics, Inc. raised?
No fundraising or offering filing from Protara Therapeutics, Inc. is on file with us.
Keep reading
More on Protara Therapeutics, Inc. and the records around it.
Protara Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/protara-therapeutics